Navigation Links
LUTRONIC® Finalizes Multi-System SPECTRA™ Deal with Unink, a Leading Tattoo Removal Chain in USA
Date:7/31/2013

Fremont, CA (PRWEB) July 31, 2013

LUTRONIC®, a global leader of lasers and therapeutic devices for aesthetic and medical applications, announced today the finalization of a multi-system SPECTRA™ deal with Unink Tattoo Removal, a leading tattoo removal chain in the USA.

Unink chose the Lutronic Spectra, a dual mode Q-switched Nd:YAG laser, because of its versatile and efficacious removal of multi-color tattoo inks. It offers four distinct wavelengths: 1064 nm, 532 nm and delivered via dye handpieces 585 nm and 650 nm. These options can target a wide variety of ink colors, including but not limited to black, red, green, blue and orange. Physicians and patients alike are impressed with the clearance achieved by the Spectra system. The technology behind the Spectra laser makes it truly unique; starting with the top-hat beam profile, which eliminates hotspots and true nanosecond pulse width, the system is developed for consistent outcomes and efficacious treatments.

“We are happy to have the right solution for the Unink Tattoo Removal franchise and are looking forward to many years of successful partnership,” shared Mark Merritt, USA Sales Director at Lutronic. “Our systems are reliable, effective, and backed by an outstanding support team. Ultimately, it is the patients who will truly benefit.”

Unink is a nationwide franchise with multiple locations and aggressive plans for expansion into new markets. By specializing exclusively in tattoo removal, the Unink technicians can focus on providing their patients with the best, most efficient treatment options at affordable prices.

“After a lot of thought and technology evaluation, Unink is proud to partner with Lutronic and choose the Spectra laser for all of our Tattoo removal clinics,” stated Stephen Heusinger, Chief Executive Officer of Unink Tattoo Removal. “Due to our high volume clinics we had to choose a partner that had a very effective system with proven reliability and superior clinical results. When we compared the product, service, training and support of Lutronic with other laser technology options, it became very clear that Lutronic and the Spectra was the right choice.”

About SPECTRA
LUTRONIC’s Dual-pulsed Q-switched Nd:YAG SPECTRA™ laser has been engineered to meet the growing demands of a busy clinic, and includes a variety of efficacious treatment options, customizable parameters, built-in safety and minimized downtimes, all at an affordable price.

With four distinct Q-switched mode wavelengths - 1064 nm, 532 nm, 585 nm, 650 nm, the robust Spectra has the versatility to provide your practice with a wide range of clinical options for treating your patients. Lutronic continually expands its treatment applications; and Spectra is the first Q-switched Nd:YAG laser cleared for the treatment of melasma. The technically advanced Spectra system offers an edge over other lasers and provides enhanced clinical outcomes.

To learn more about the Spectra please visit: http://www.lutronic.com/SPECTRA.

About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 15 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 130 current and pending patents worldwide. With more than 230 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.

Learn More: http://www.lutronic.com

About UNINK Tattoo Removal
Unink Tattoo Removal is recognized as the fastest growing chain of tattoo removal clinics in the United States. The company is headquartered in Dallas, Texas, and backed by an investment firm with over 15 years of experience in healthcare sector investments. For investor or press information, contact Unink at 855-Ink-Away (855-465-2929), or Stephen Heusinger, CEO at sheusinger(at)unink(dot)com.

Learn more: http://www.uninktattooremoval.com

Contact:
Tracy Evleshin
Global Marketing Communications Director
850 Auburn Ct., Fremont CA 95134

Read the full story at http://www.prweb.com/releases/2013/7/prweb10985957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lutronic® Announces FDA Clearance for INFINI™, an Ideal Solution for Wrinkle Reduction Through 3-D Volumization
2. Cloud Medical Doctor Software Corporation Finalizes Acquisition of Doctors Network of America and Expands its Medical Billing Services West
3. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
4. Diabetes drug could treat leading cause of blindness
5. Pneumonia and preterm birth complications are the leading causes of childhood death
6. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
7. Dr. Edmund Lipskis & Dr. Lynn Lipskis Will be Featured On New National Television Show Entitled: “Leading The Field” World Class Experts Share Their Tips & Advice
8. ACR: Medical imaging study in health affairs incomplete and potentially misleading
9. Poorly-performing hand implants unacceptable says leading medical journal
10. Leading cancer specialists from Europe and beyond recognized at ESMO 2012
11. WSU researchers discover mechanism leading from trichomoniasis to prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: